Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,180,269 papers from all fields of science
Search
Sign In
Create Free Account
cytarabine/gemtuzumab ozogamicin/mitoxantrone
Known as:
ARA-C/CMA-676/DHAD
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Cytarabine
Gemtuzumab ozogamicin
Mitoxantrone Hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
L. Fostvedt
,
J. Hibma
,
J. Masters
,
E. Vandendries
,
A. Ruiz-Garcia
Clinical pharmacology and therapy
2019
Corpus ID: 148569098
Gemtuzumab ozogamicin (Mylotarg; Pfizer, New York, NY) was the first antibody–drug conjugate to be approved for CD33‐positive…
Expand
2019
2019
Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis…
V. Ho
,
A. S. Martin
,
+6 authors
W. Saber
Biology of Blood and Marrow Transplantation
2019
Corpus ID: 209524653
2018
2018
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
Naghmeh Niktoreh
,
Beate Lerius
,
+9 authors
M. Rasche
Haematologica
2018
Corpus ID: 51955713
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We…
Expand
2014
2014
Final Analysis of the ALFA 0701 Study
S. Castaigne
,
C. Pautas
,
+11 authors
H. Dombret
2014
Corpus ID: 78432464
Aim: The first analysis of the ALFA-0701 study, testing the addition of gemtuzumab ozogamicin (GO) to standard treatment in de…
Expand
2011
2011
Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
E. Jager
,
V. V. D. van der Velden
,
J. te Marvelde
,
R. Walter
,
Z. Agur
,
V. Vainstein
PLoS ONE
2011
Corpus ID: 15334058
Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute…
Expand
2008
2008
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
L. Fianchi
,
L. Pagano
,
+8 authors
G. Leone
Annals of Oncology
2008
Corpus ID: 8467300
BACKGROUND Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated…
Expand
Review
2007
Review
2007
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
J. McKoy
,
C. Angelotta
,
+9 authors
F. Giles
Leukemia research : a Forum for Studies on…
2007
Corpus ID: 22169622
2007
2007
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience
D. Pastore
,
P. Carluccio
,
+8 authors
V. Liso
Annals of Hematology
2007
Corpus ID: 25414686
We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of…
Expand
Review
2004
Review
2004
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
C. Nabhan
,
L. Rundhaugen
,
+4 authors
M. Tallman
Annals of Oncology
2004
Corpus ID: 20962962
BACKGROUND Gemtuzumab ozogamicin (GO) is approved for the treatment of older adults with acute myeloid leukemia in first relapse…
Expand
2001
2001
Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . .
L. Gordon
Bone Marrow Transplantation
2001
Corpus ID: 21863561
Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . .
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE